ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2029

Reliability of Scoring a Disease Damage Measure for Juvenile Localized Scleroderma

Kathryn S. Torok1, Suzanne C. Li2, Christina Kelsey3, Mara L Becker4, Fatma Dedeoglu5, Robert C. Fuhlbrigge6, Gloria Higgins7, Sandy D. Hong8, Maria F. Ibarra9, Ronald Laxer10, Thomas G. Mason II11, Marilynn G. Punaro12, Elena Pope13, C. Egla Rabinovich14 and Katie G. Stewart12, 1Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 3Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, 5Division of Immunology, Boston Children's Hospital, Boston, MA, 6Pediatric Rheumatology, Childrens Hospital, Boston, MA, 7Pediatric Rheumatology NATIONWIDE CHILDRENS HOSPITAL, PRCSG-Cincinnati Children's Hospital Medical Center, Columbus, OH, 8Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, 9Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 10Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 11Rheumatology, Mayo Clinic Rochester, Rochester, MN, 12Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 13Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, 14Pediatric Rheumatology, Duke University Medical Center, Durham, NC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Outcome measures, pediatric rheumatology and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: .   

In order to more accurately capture disease activity and damage in juvenile Localized Scleroderma (jLS) and to develop an accepted outcome measure for treatment protocols, an LS-focused Childhood Arthritis and Rheumatology Research Alliance subgroup developed clinical disease activity and damage measures.  The objective of this abstract is to discuss the assessment of the reliability and validity of the LS Damage Score in jLS.  The LS Damage Score includes four domains (dermal atrophy, subcutaneous atrophy, dyspigmentation {hyper/hypo pigmentation}, and skin thickness of lesion center) which are scored for all affected sites.

Methods:

Thirteen pediatric rheumatologists and a dermatologist attended a 2-day workshop meeting to review LS clinical measures.  Raters ranked 13 jLS patients on damage domains at 2 time points.  Patients were presented to raters in random order in efforts to reduce recall bias.  For each patient, raters were told which anatomic sites to assess (1-2/patient).  Physicians also completed Physician Global Assessment of Disease for Activity and Damage (PGA-A; PGA-D).  To examine construct validity, we hypothesized that the LS Damage Score would have a moderate correlation to PGA-D and a low correlation to PGA-A.  Spearman’s rho was calculated to quantify the relationship with clinical parameters, and intraclass correlation coefficients (ICC) were examined to determine inter/intra rater reliability (0.20-0.39 low, 0.40-0.59 moderate, 0.60-0.79 high). 

Results:

Median age of LS patients was 13 years (IQR = 9.5-17) and the most common subtype was linear scleroderma (4 limb, 4 head).  Mean LS Damage Scores ranged from 3.96 to 16.46 (max score 24); PGA-D ranged from 14.54 to 53.48 (max score 100).  There was a low correlation between the LS Damage Score and both PGA-D and PGA-A (ρ = .11, ρ = .14).  Raters demonstrated moderate/high inter and intra-rater reliability for the LS Damage score, and low/moderate inter and intra-rater reliability for PGA-D. Among the domains, hypopigmentation showed the lowest inter-rater reliability.(Table1) 

Table 1: Inter-rater and intra-rater reliability of LS Damage score

Domains

 Round 1

ICC (95% CI)

Round 2

ICC (95% CI)

LS Damage Score:

 

 

          Inter-rater reliability

0.56 (.37, .79)

0.63 (.43, .83)

          Intra-rater reliability (median, [range])

 

0.81 [ 0.53 – 0.93]

PGA-D:

 

 

          Inter-rater reliability

0.19 (.08, .44)

0.28 (.14, .54)

          Intra-rater reliability (median, [range])

 

0.51 [ 0.09 -0.75]

LS Damage Score parameters: inter-rater reliability

 

 

         Dermal Atrophy

0.37 (.23, .58)

0.48 (.33, .67)

         Subcutaneous Atrophy

0.42 (.28, .62)

0.51 (.36, .70)

         Dyspigmentation:

                     Hyperpigmentation

                     Hypopigmentation

0.66 (.52, .81)

0.22 (.12, 40)

0.71 (.58, .84)

0.24 (.13, .42)

         Skin Thickness of lesion center

0.61 (.46, .77)

0.53 (.39, .73)

Conclusion:   

The LS Damage Score had moderate-high reliability between and among raters, with hyperpigmentation, skin thickness center, and dermal atrophy contributing most to the total score.  Overall, the inter-rater agreement of damage components increased in session 2. The PGA-D performed well within the rater’s repeat assessment, but poorly in regards to inter-rater reliability. The poor correlation between PGA-D and LS Damage Score may reflect MD inclusion of extracutaneous manifestations (ECM), such as facial disfigurement.   In post-hoc analysis, when patients with facial linear scleroderma were removed, the correlations of PGA-D with LS Damage Score increased (ρ = .317).  Additional studies are needed to fully evaluate this measure.


Disclosure:

K. S. Torok,
None;

S. C. Li,
None;

C. Kelsey,
None;

M. L. Becker,
None;

F. Dedeoglu,
None;

R. C. Fuhlbrigge,
None;

G. Higgins,
None;

S. D. Hong,
None;

M. F. Ibarra,
None;

R. Laxer,

Novartis Pharmaceutical Corporation,

2;

T. G. Mason II,
None;

M. G. Punaro,
None;

E. Pope,
None;

C. E. Rabinovich,
None;

K. G. Stewart,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-of-scoring-a-disease-damage-measure-for-juvenile-localized-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology